Protriptyline – Kodiac biolabs

Plain-language summaryIntrigue 41 / 100

Protriptyline (Vivactil) is a secondary-amine tricyclic antidepressant from 1967 with one defining quirk: it is activating rather than sedating, which is the opposite of nearly every other drug in the class. The activating profile comes from preferential norepinephrine pump blockade combined with relatively little antihistamine activity. That made it historically useful for depressed patients with hypersomnia who needed alertness rather than further sedation. It has a long half-life because the liver metabolizes it slowly. Rarely prescribed now, displaced by SNRIs like duloxetine that achieve similar activation with much better tolerability. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

A 1967-approved TCA with a niche activating profile and almost no modern research frontier

Look, protriptyline is a real drug with a real effect. FDA approved in 1967, still prescribed, pharmacologically coherent. The case for it has always rested on a single differentiating fact: among the tricyclics, it doesn’t sedate. Most of the class leans heavily sedating via H1 blockade, but protriptyline’s relatively low H1 affinity and its NET-dominant profile (Ki around 1.4 nM at the norepinephrine transporter versus roughly 20 nM at SERT) tip the balance toward activation. That matters clinically, particularly in depression complicated by hypersomnia or narcolepsy-related mood disorder. The half-life situation is unusual too: 54 to 92 hours is long even by TCA standards, driven by sluggish CYP2D6 metabolism, which creates both a forgiving dosing window and a complicated clearance picture when coadministering.

Here’s the thing though: none of that is news. The pharmacology was described and characterized decades ago. The NET-over-SERT selectivity angle has been studied far more rigorously in compounds like reboxetine and atomoxetine, and the wakefulness-promoting space now belongs to orexin-pathway agents, modafinil, and the solriamfetol class. If you’re building a research program around activating antidepressant pharmacology, you’re not reaching for protriptyline as your probe. It’s burdened by the full TCA liability profile: muscarinic blockade, sodium channel effects, alpha-1 antagonism, narrow therapeutic index. These are not features that help you isolate a mechanism.

The evidence base is approved-drug-real, which means there’s clinical data going back to the 1960s. But TCA-era trials dont meet modern methodological standards. You’re looking at small, non-blinded, poorly-controlled studies by today’s metrics. Multi-decade literature exists, but a lot of it is descriptive case series or comparisons to other TCAs, not placebo-controlled designs with preregistered endpoints. The narcolepsy-depression comorbidity literature is genuinely thin and mostly observational.

We think the honest bench value here is narrow: if youre specifically studying secondary amine TCA pharmacokinetics, CYP2D6-driven extended half-life effects, or the NET-dominant TCA subclass as a historical reference point, protriptyline has a role. That’s a specific niche, not a broad research priority. For anything involving the activating-antidepressant mechanism today, the tools have moved on. Protriptyline remains useful the way a well-characterized historical reference standard is useful: occasionally, deliberately, and not as a centerpiece of a serious contemporary program.

Novelty: 10
Mechanism promise: 20
In-category differentiation: 25
Evidence quality: 45
Translational signal: 48
Research bench value: 28

Rationale Protriptyline scores low across novelty and differentiation because it is a mid-century TCA with no mechanism surprise and no serious modern competition driving renewed investigation; its higher NET selectivity is real but bupropion and modern SNRIs have absorbed that research territory entirely. Evidence quality and translational signal get modest credit for FDA approval and clear clinical effect, but neither dimension rescues the compound’s place in a contemporary research priority stack.

Tricyclic antidepressant (secondary amine, activating)

A secondary amine TCA distinguished by activating rather than sedating subjective profile; useful in depression with hypersomnia.

Abstract

Protriptyline (N-methyl-3-(5H-dibenzo[a,d]cyclohepten-5-yl)propan-1-amine; CAS 438-60-8; molecular formula C19H21N; molecular weight 263.38) is a secondary amine TCA approved by the FDA in 1967 under the trade name Vivactil. Distinct among TCAs for an activating subjective profile that contrasts with the sedation typical of the class; the activating profile is attributed to relatively higher NET-to-SERT selectivity and reduced H1 antagonism. NET Ki approximately 1.4 nM, SERT Ki approximately 20 nM. Plasma half-life is exceptionally long (54 to 92 hours) owing to slow CYP2D6 metabolism. The activating profile makes protriptyline a niche choice for depression with prominent hypersomnia or fatigue, including narcolepsy-associated depression where the wakefulness-promoting effect is therapeutic. Off-target activity is otherwise typical of secondary amine TCAs: muscarinic, mild H1, alpha-1, and sodium channel block. Approved for major depressive disorder; rarely first-line today owing to TCA-class limitations. Used as a reference compound for activating TCA pharmacology and in narcolepsy-related comorbidity research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-221Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.